Direct
NAV (06-Sep-24)
Returns (Since Inception)
Fund Size
₹69 Cr
Expense Ratio
1.21%
ISIN
INF397L01LK4
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
28 Feb 2019
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+54.40%
+54.79% (Cat Avg.)
3 Years
+14.88%
+18.09% (Cat Avg.)
5 Years
+25.83%
+29.12% (Cat Avg.)
Since Inception
+23.23%
— (Cat Avg.)
Equity | ₹67.48 Cr | 97.54% |
Others | ₹1.7 Cr | 2.46% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹8.09 Cr | 11.29% |
Piramal Pharma Ltd | Equity | ₹4.81 Cr | 6.71% |
Artemis Medicare Services Ltd Ordinary Shares | Equity | ₹4.58 Cr | 6.39% |
Torrent Pharmaceuticals Ltd | Equity | ₹4.32 Cr | 6.03% |
Glenmark Pharmaceuticals Ltd | Equity | ₹4.03 Cr | 5.63% |
Cipla Ltd | Equity | ₹3.8 Cr | 5.30% |
Mankind Pharma Ltd | Equity | ₹3.53 Cr | 4.93% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹3.23 Cr | 4.51% |
Abbott India Ltd | Equity | ₹3.1 Cr | 4.32% |
Alkem Laboratories Ltd | Equity | ₹2.98 Cr | 4.16% |
Ipca Laboratories Ltd | Equity | ₹2.97 Cr | 4.14% |
Zydus Lifesciences Ltd | Equity | ₹2.94 Cr | 4.10% |
Divi's Laboratories Ltd | Equity | ₹2.83 Cr | 3.95% |
Global Health Ltd | Equity | ₹2.68 Cr | 3.74% |
Apollo Hospitals Enterprise Ltd | Equity | ₹2.49 Cr | 3.47% |
Treps | Cash - Repurchase Agreement | ₹2.36 Cr | 3.30% |
Suven Pharmaceuticals Ltd | Equity | ₹2.23 Cr | 3.12% |
Dr Reddy's Laboratories Ltd | Equity | ₹2.09 Cr | 2.91% |
Laurus Labs Ltd | Equity | ₹2 Cr | 2.79% |
Navin Fluorine International Ltd | Equity | ₹1.73 Cr | 2.41% |
Metropolis Healthcare Ltd | Equity | ₹1.67 Cr | 2.33% |
Syngene International Ltd | Equity | ₹1.38 Cr | 1.93% |
Yatharth Hospital and Trauma Care Services Ltd | Equity | ₹0.99 Cr | 1.38% |
Neuland Laboratories Limited | Equity | ₹0.72 Cr | 1.00% |
Neogen Chemicals Ltd | Equity | ₹0.72 Cr | 1.00% |
Net Receivables / (Payables) | Cash | ₹-0.6 Cr | 0.84% |
Large Cap Stocks
37.88%
Mid Cap Stocks
24.28%
Small Cap Stocks
34.38%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹66.72 Cr | 93.13% |
Basic Materials | ₹2.44 Cr | 3.41% |
Standard Deviation
This fund
15.69%
Cat. avg.
15.96%
Lower the better
Sharpe Ratio
This fund
0.60
Cat. avg.
0.79
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.44
Higher the better
Since July 2023
ISIN | INF397L01LK4 | Expense Ratio | 1.21% | Exit Load | 1.00% | Fund Size | ₹69 Cr | Age | 28 Feb 2019 | Lumpsum Minimum | ₹5,000 | Fund Status | Open Ended Investment Company | Benchmark | BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Dividends are added to the investor’s income and taxed according to their respective tax slabs. Additionally, if an investors dividend income exceeds INR 5,000 in a financial year, the fund house deducts a 10% Tax Deducted at Source (TDS) before distributing the dividend.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹14.97 Cr | 55.2% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.0% | 1.0% | ₹791.70 Cr | 56.3% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹791.70 Cr | 54.1% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹31.78 Cr | 52.5% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹183.39 Cr | 55.6% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹183.39 Cr | 52.7% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2560.38 Cr | 53.4% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2560.38 Cr | 51.2% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹798.61 Cr | 52.8% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹18.87 Cr | 51.4% |
Total AUM
₹1,609 Cr
Address
4th Floor, Industrial Assurance Building, Mumbai, 400 020
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
LIC MF Gold ETF FOF Direct Growth High Risk | 0.3% | 1.0% | ₹54.40 Cr | 21.1% |
LIC MF Equity Savings Fund Direct Growth Moderately High risk | 1.0% | 1.0% | ₹19.38 Cr | 16.1% |
LIC MF Nifty Next 50 Index Fund Direct Growth Very High Risk | 0.3% | 0.0% | ₹95.83 Cr | 63.7% |
LIC MF Focused 30 Equity Direct Growth Very High Risk | 1.6% | 1.0% | ₹151.43 Cr | 31.6% |
LIC MF Long Term Value Fund Direct Growth Very High Risk | 1.6% | 1.0% | ₹123.47 Cr | 43.3% |
LIC MF Healthcare Fund Direct Growth Very High Risk | 1.2% | 1.0% | ₹69.18 Cr | 54.4% |
LIC MF Small Cap Fund Direct Growth Very High Risk | 1.5% | 1.0% | ₹318.40 Cr | 53.5% |
LIC MF Midcap Fund Direct Growth Very High Risk | 1.6% | 1.0% | ₹319.71 Cr | 51.3% |
LIC MF Dividend Yield Fund Direct Growth Very High Risk | 1.4% | 1.0% | ₹330.46 Cr | 60.2% |
Your principal amount will be at Very High Risk